Stocktoria
Invivyd, Inc. IVVD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-08-06
Chart by TradingView
2/9
Piotroski F — financial health
-0.36
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $53.4M | $25.4M | $0 | — | — |
| Operating income | -$55.6M | -$176.9M | -$212.8M | -$248.0M | -$226.9M |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | -$226.8M |
| Operating cash flow | -$58.1M | -$170.5M | -$173.2M | -$220.0M | -$184.7M |
| Free cash flow | -$58.3M | -$170.6M | -$173.8M | -$221.7M | -$184.8M |
| Total assets | $276.9M | $129.5M | $229.2M | $383.2M | $620.1M |
| Total liabilities | $35.3M | $62.0M | $51.7M | $27.2M | $62.1M |
| Shareholders' equity | $241.5M | $67.5M | $177.5M | $356.0M | $558.0M |
| Ratios | |||||
| Operating margin | -104.0% | -696.8% | — | — | — |
| Net margin | -98.2% | -669.4% | — | — | — |
| FCF margin | -109.1% | -672.2% | — | — | — |
| Return on assets | -19.0% | -131.2% | -86.7% | -63.0% | -36.6% |
| Return on equity | -21.7% | -251.6% | -111.9% | -67.8% | -40.6% |
| Current ratio | 7.24 | 1.62 | 4.47 | 15.06 | 9.94 |
| Revenue growth | 110.5% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 846,265 | $1.1M |
| Point72 Asset Management, L.P. | 43,931 | $57,110 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.36 (distress)
- Working capital / assets 0.77
- Retained earnings / assets -3.447
- EBIT / assets -0.201
- Equity / liabilities 6.834
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001832038 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.